Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
01 6Rexulti
02 12Rexulti/Rxulti
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 426
2019 Revenue in Millions : 369
Growth (%) : 15
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 434
2020 Revenue in Millions : 419
Growth (%) : 9
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 560
2021 Revenue in Millions : 434
Growth (%) : 29
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 652
2022 Revenue in Millions : 560
Growth (%) : 16
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 721
2023 Revenue in Millions : 652
Growth (%) : 11
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 18
Growth (%) : New Launch
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 212
2016 Revenue in Millions : 140
Growth (%) : 51
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 258
2017 Revenue in Millions : 187
Growth (%) : 38%
Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 341
2018 Revenue in Millions : 258
Growth (%) : 32
